Compare whole blood and PBMC approaches for replication-competent lentiviral vector (RCL) monitoring.

Monitoring replication-competent lentiviral vectors (RCLs) is an important component of gene therapy safety assessments. This poster compares whole blood and peripheral blood mononuclear cell (PBMC)–based approaches for RCL quantification, evaluating analytical performance, sensitivity, precision, and workflow considerations to support clinical trial testing.

Key highlights include:

• Comparison of whole blood and PBMC-based methods for RCL quantification
• Evaluation of assay sensitivity, precision, accuracy, and linearity
• Assessment of workflow efficiency and sample handling considerations
• Advantages of whole blood as a simplified approach for RCL monitoring
• Practical insights for selecting an appropriate sample matrix for gene therapy clinical trials

As gene therapies continue to advance, reliable and efficient safety testing is essential. Learn how whole blood and PBMC-based approaches compare for RCL monitoring and the factors to consider when selecting the optimal strategy for clinical development.